SpaceX~$1TSpaceX~$1T
Insider Buying
Subscribe
All stock lists
WGS

GeneDx Holdings Corp. (NASDAQ:WGS)

US · Delayed Price · Currency is USD
Healthcare · Medical - Diagnostics & Research
$45.46-$3.78 (-7.68%)
 
Market cap
$1.36B
Insider Score
Health Score
Analyst consensus
Listed since
Nov 4, 2020
Website
Market Cap$1.36B-71.8%
Revenue (ttm)$460.78M+14.6%
Net Income-$111.05M-5431.2%
EPS-$3.76-6366.7%
Shares Out29.97M
PE Ration/a
Forward PE38.36
Dividendn/a
Ex-Dividend Daten/a
Volume912,641
Open$47.85
Previous Close$49.24
Day's Range$45.19 - $49.10
52-Week Range$32.21 - $170.87
Beta1.99
AnalystsBuy
Price Target$80.25(+76.53%)
Earnings DateFeb 22, 2027

About WGS

GeneDx Holdings Corp., a genomics company, provides genetic testing services. The company primarily offers pediatric and rare disease diagnostics with a focus on whole exome and genome sequencing, as well as data and information services. It also develops an AI-based platform for next generation sequencing analysis, interpretation, and clinical reporting for rare disease, hereditary risk, and cancer testing. GeneDx Holdings Corp. was founded in 2000 and is headquartered in Stamford, Connecticut.

Address
North Tower, Stamford, CT, 06902, US
Market Cap
1.36 billion
Employees
1,300
Industrial Classification
Medical - Diagnostics & Research

What Are Insiders Doing?

Open-market buy / sell balanceNet Selling
Sold
$2.07M
Bought
$0

View the trades behind this meter — each links to its SEC Form 4 →

Open-market Form 4 purchases (code P) vs sales (code S) on file for this company. Grants, option exercises and tax withholdings are excluded. Informational only.

Analyst consensus

Moderate Buy
2 Buy0 Hold0 SellAvg target $79.60 (+55.4%)

2 firms rating WGS in the last 3 months, one vote each. Issuer-paid research is not counted.

Financial Health Score
Fair
From WGS’s reported statements · Q3 2026 (trailing 12 months)

Next catalysts

1 Day
-7.68%
5 Days
-12.58%
1 Month
-32.29%
6 Months
-3.91%
1 Year
-71.78%

$WGS stock is featured in our Insider Score Rankings, and Insider Trades datasets.

→ All Stock Lists

Recently reported changes in WGS holdings by institutional investors

Scanning latest 13F filings…

Latest 0 13F filings · Source: SEC EDGAR

View all institutional owners →

Insider Trading

Quarterly net insider trading by WGS's directors and management

Net Shares Purchased by Insiders−20k−10k02025Q42026Q12026Q22026Q32026Q4

Source: SEC EDGAR (Form 4)

Corporate Lobbying

WGS Estimated quarterly lobbying spending

Source: U.S. Senate LDA

WGS Revenue by Segment

$123.19MTotal
Diagnostic test revenue:$120.06M97.46%
Other$3.04M2.47%
Self-pay patients$93.00K0.08%

As of: Q3 2026 (Sep 30, 2026) · Source: SEC EDGAR (10-Q)

U.S. Patents

New WGS patent grants

Loading patent grants…

Source: USPTO Open Data Portal

Government Contracts

Estimated quarterly amount awarded to WGS from public contracts

Source: USAspending.gov

Top ETF Holders

ETFs with the largest estimated holdings in WGS

ARKKARK Innovation ETF$165.00M
VTIVanguard Morningstar Total Stock Market ETF$36.08M
ARKGARK Genomic Revolution ETF$29.14M
IWMiShares Russell 2000 ETF$24.40M
VXFVanguard Extended Market ETF$18.01M
FESMFidelity Enhanced Small Cap ETF$10.59M

Estimated from each fund’s disclosed top holdings × AUM

Bull Case vs Bear Case

AI-generated from WGS’s recent data — informational, not investment advice

Generating analysis…

What’s Behind the Score

Insider Activity
48% of score
0
Analyst Ratings
32% of score
99
News & Sentiment
20% of score
58

News check: CEO transition and sequencing adoption gains offset by post-earnings 16.6% stock decline and cash burn concerns.

Recent Insider Activity

Buys
0
Sells
16
Buy Value
$0
Distinct Buyers
0

Insider Score Trend Over Time

+0.0 since Sep 4
0255075100Sep 4 — Insider Score 0.0Sep 5 — Insider Score 0.0Sep 6 — Insider Score 0.0Sep 7 — Insider Score 0.0Sep 8 — Insider Score 0.0Sep 9 — Insider Score 0.0Sep 10 — Insider Score 0.0Sep 11 — Insider Score 0.0Sep 12 — Insider Score 0.0Sep 13 — Insider Score 0.0Sep 14 — Insider Score 0.0Sep 15 — Insider Score 0.0Sep 16 — Insider Score 0.0Sep 17 — Insider Score 0.0Sep 18 — Insider Score 0.0Sep 19 — Insider Score 0.0Sep 20 — Insider Score 0.0Sep 21 — Insider Score 0.0Sep 22 — Insider Score 0.0Sep 23 — Insider Score 0.0Sep 24 — Insider Score 0.0Sep 25 — Insider Score 0.0Sep 26 — Insider Score 0.0Sep 27 — Insider Score 0.0Sep 28 — Insider Score 0.0Sep 29 — Insider Score 0.0Sep 30 — Insider Score 0.0Oct 1 — Insider Score 0.0Oct 2 — Insider Score 32.0Oct 3 — Insider Score 0.0Oct 4 — Insider Score 0.0Sep 4Sep 19Oct 4

Composite Insider Score (0–100) recomputed on each scoring run from live SEC Form 4 data.

Frequently Asked Questions

Disclaimer — Informational only — not investment advice. Insider transaction data is sourced from SEC Form 4 filings; market data from public feeds and may be delayed. The Insider Score is a proprietary score for research purposes and does not predict future performance. Always do your own research.

ETFs that hold this stock

ARKGARK Genomic Revolution ETF1.65%
GNOMGlobal X - Genomics & Biotechnology ETF1.09%
XHSState Street SPDR S&P Health Care Services ETF0.98%
ARKKARK Innovation ETF0.84%
TSMEThrivent Small-Mid Cap Equity ETF0.78%
GNMXCorgi ETF Trust I - Corgi Genomics & Precision Medicine ETF0.60%
EKGFirst Trust Nasdaq Lux Digital Health Solutions ETF0.50%
FSMLFranklin Small Cap Enhanced ETF0.37%
WCEOHypatia Women CEO ETF0.37%
SSMGVirtus Silvant Small/Mid Growth ETF0.27%
FSEGFidelity Enhanced Small Cap Growth ETF0.22%
FYCFirst Trust Small Cap Growth AlphaDEX Fund0.19%

Weight is the stock’s share of each fund’s holdings.